Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

Inclusion Criteria: * BMI (body mass index) ≥28kg/m2 * Consent informed and signed * Pathologically confirmed as endometrial atypical hyperplasia * Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements * Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time Exclusion Criteria: * Diagnosed as type 2 diabetes * Diabetic ketoacidosis * History of acute pancreatitis * Have a history or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2 (MEN2) * Combined with severe medical disease or severely impaired liver and kidney function * Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone- dependent tumors that cannot be used with progesterone * Those who require hysterectomy or other methods other than conservative treatment with drugs * Known or suspected pregnancy * Currently suffering from pelvic inflammatory disease or diagnosed as pelvic inflammatory disease * Lower reproductive system infection * abnormal cervical dysplasia * Congenital or acquired uterine abnormalities, including fibroids that deform the uterine cavity * Allergic to any parts of LNG-IUS components * The uterine cavity is too large (average diameter is over 7cm) or the history of LNG-IUS fal…